At a glance
- Palmitoyl tripeptide-5 (Syn-Coll) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 4 publications mentioning it, including 0 randomized controlled trials and 0 animal-only studies.
- ClinicalTrials.gov lists 2 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Supramolecular collagen nanoparticles for anti-wrinkle, skin whitening, and moisturizing effects.
- Delivery of Active Peptides by Self-Healing, Biocompatible and Supramolecular Hydrogels.
- Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.
- Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 2
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types. | Completed | Phase 4 | November 20, 2023 |
| Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation | Completed | N/A | October 29, 2018 |
All 2 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.